Rabin Cone Contrast Test™

Early Detection & Disease Management

The Rabin Cone Contrast Test™ is a quantifiable assessment of cone and visual pathway function. It is the most advanced color vision test, providing a more complete understanding of disease progression, allowing for earlier diagnosis and treatment.

Reimbursable with CPT Code 92283

See What You’ve Been Missing

Earlier Detection

One of the earliest detectors of change from AMD, glaucoma, diabetic eye disease, and high-risk medication toxicity

Sub-clinical Progression

Accurately indicates its severity and its progression even in patients with no visible changes on structural tests

Improvement

Proven in clinical trials to demonstrate functional improvement from therapies

Reimbursable

Billable using CPT Code 92283, extended color vision, anomaloscope or equivalent

Earlier Detection

Beginning treatment and making life-style changes earlier can alter the trajectory of disease. Unfortunately, most patients are not diagnosed until they already have permanent structural damage with no opportunity to reverse accompanying vision loss.

The goal in all eye disease, whether AMD, glaucoma, or diabetic eye disease is to slow or halt advancement. Treatments exist that can stop progression and even reverse functional loss, but only if administered early enough.

The Rabin Cone Contrast Test is one of the earliest tests to detect vision loss related to disease, allowing you to treat before irreversible damage occurs.

The Rabin Cone Contrast Test™ is one of the earliest tests to detect vision loss

Sub-clinical Progression

The Rabin Cone Contrast Test accurately indicates severity of color deficiencies from disease and its progression even in patients with no changes visible on structural tests.  Duke University showed the Rabin Cone Contrast Test detected sub-clinical advancement in intermediate AMD in as little as 12 months with no changes on the OCT. Detecting progression at its earliest stage improves risk assessment and enables you to make treatment changes earlier, providing the best possible patient care.

The Rabin Cone Contrast Test™ detected sub-clinical advancement in intermediate AMD within 12 months.

Improvement

Demonstrating vision loss can be a strong motivator for patients to begin treatment, since they can “see what they can’t see.” The Rabin Cone Contrast Test™ quantifies early visual changes from disease. Even when visual acuity is not yet affected, the Rabin Cone Contrast Test clearly demonstrates vision loss.

While structural tests show stability, only functional tests can show improvement.

The Rabin Cone Contrast Test has been proven in clinical trials to clinical trials to measure improvement from therapies, including nutraceutical and to anti-VEGFs. Progression reports demonstrate improvement, providing motivating evidence of the positive effects of treatment.

Reimbursable

The Rabin Cone Contrast Test™ is billable using CPT Code 92283, extended color vision, anomaloscope or equivalent. With ICD-10 codes covering retina, glaucoma, neuro and cataracts, most practices return their investment with just 150 patients! And there is no mutual exclusivity with other tests, so the Rabin Cone Contrast Test can be billed on the same day as other tests, including OCT or fundus photography.

When used in screening exams, a positive result on the Rabin Cone Contrast Test™ is medical necessity for further testing, increasing utilization of your other billable tests.

What our customers are saying

  • “I can’t imagine not having the Rabin Cone Contrast. It has been so helpful for optic nerve disease, differentiation of glaucoma vs optic nerve pathology, following up post recovery, cone rod dystrophy, Stargardt, Best, and any maculopathy. Amazing for further investigating glaucoma damage with OCT and visual field images. Great tool. It’s extremely important to have this test in our offices.”

    Ami Ranani, OD | Somers Eye Center, Somers, NY

    MORE TESTIMONIALS

  • “I’ve been more than pleased with the ROI, ease of use, data gathered, and impact on patient care of the Rabin Cone Contrast Test.”

    Christopher Lopez, OD | Griebenow Eyecare, New London, WI

    MORE TESTIMONIALS

  • “I see the RABIN CCT as a leading indicator, and I do weigh it heavily when I am considering earlier intervention. Glaucoma in particular, I see that the CCT often shows loss before other functional tests, and certainly before structural loss measures.”

    Jeffery Martin, OD | Clear View Vision Care, Tucson, AZ

    MORE TESTIMONIALS

  • "The Rabin Cone Contrast test has become an essential part of our posterior segment management for patients with diabetes and diabetic retinopathy. A quick, patient friendly, innovative color vision test that looks at all 3 cones - red, green and blue - it has revealed functional changes and impairments in patients before structural disease presents itself."

    Nate Lighthizer, OD | Assoc. Dean, NSI OK College of Opt, Tahlequah, OK

    MORE TESTIMONIALS